Get started
Author

Giulia Rotta

Observed name: Rotta, Giulia
ORCID: 0000-0001-6897-9225
Observed ORCID: 0000-0001-6897-9225
OpenAlex ID: A5073186508
A Comparative Analysis of Fibroblast Activation Protein-Targeted Small Molecule–Drug, Antibody–Drug, and Peptide–Drug Conjugates
2023 · Aureliano Zana, Claudia Puig-Moreno, et al. · Bioconjugate Chemistry · 35
Pivotal role of the protein corona in the cell uptake of fluorinated nanoparticles with increased sensitivity for 19 F-MR imaging
2023 · Lodovico Gatti, Cristina Chirizzi, et al. · Nanoscale Advances · 12
PDF
Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen
2023 · Louis Plüss, Frederik Peissert, et al. · mAbs · 11
PDF
Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer
2024 · Abdullah Elsayed, Louis Plüss, et al. · Molecular Cancer Therapeutics · 10
PDF
A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors
2024 · Giulia Rotta, Ettore Gilardoni, et al. · EMBO Molecular Medicine · 10
PDF
Cytokine Biopharmaceuticals with “Activity-on-Demand” for Cancer Therapy
2024 · Giulia Rotta, Emanuele Puca, et al. · Bioconjugate Chemistry · 6
Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein
2025 · Giulia Rotta, Eleonora Prodi, et al. · Journal for ImmunoTherapy of Cancer · 5
Combination with Immunocytokines Enhances the Anticancer Activity of Small Molecule Drug Conjugates and Radioligand Therapeutics Targeting Fibroblast Activation Protein
2026 · Matilde Bocci, Laura Lucaroni, et al. · Molecular Pharmaceutics · 3
Tripokin: A multi‐specific immunocytokine for cancer immunotherapy
2024 · Eleonora Prodi, Riccardo Corbellari, et al. · International Journal of Cancer · 2
PDF
Abstract 5744: Decreasing toxicity of immunocytokines by transient and selective inhibition of their intracellular signaling activation
2023 · Giulia Rotta, Ettore Gilardoni, et al. · Cancer Research · 2
Expression patterns of fibroblast activation protein and extra-domain B fibronectin in canine malignant tumors
2026 · Silvia Dell’Aere, Elisa Maria Gariboldi, et al. · Frontiers in Veterinary Science · 1
PDF
Figure S1 from Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer
2026 · Abdullah Elsayed, Louis Plüss, et al.
Movie S2 from Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer
2026 · Abdullah Elsayed, Louis Plüss, et al.
Figure S2 from Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer
2026 · Abdullah Elsayed, Louis Plüss, et al.
Figure S3 from Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer
2026 · Abdullah Elsayed, Louis Plüss, et al.
Movie S4 from Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer
2026 · Abdullah Elsayed, Louis Plüss, et al.
Movie S3 from Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer
2026 · Abdullah Elsayed, Louis Plüss, et al.
Movie S1 from Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer
2026 · Abdullah Elsayed, Louis Plüss, et al.
Figure S4 from Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer
2026 · Abdullah Elsayed, Louis Plüss, et al.
Data from Immunocompetent Mouse Models of Cancer Reveal the Superiority of Cellular Targets over Stromal Targets for the Development of Anticancer Bispecific Antibodies
2026 · Stefanie K. Pfister, Frauke Seehusen, et al.
SI Figures 1-12 and SI methods from Immunocompetent Mouse Models of Cancer Reveal the Superiority of Cellular Targets over Stromal Targets for the Development of Anticancer Bispecific Antibodies
2026 · Stefanie K. Pfister, Frauke Seehusen, et al.
Immunocompetent Mouse Models of Cancer Reveal the Superiority of Cellular Targets over Stromal Targets for the Development of Anticancer Bispecific Antibodies
2025 · Stefanie K. Pfister, Frauke Seehusen, et al. · Molecular Cancer Therapeutics
Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein
2025 · Rotta, Giulia, Prodi, Eleonora, et al. · Zurich Open Repository and Archive (University of Zurich)
Combinatorial strategy to generate antibody-cytokine fusions with "activity-on-demand" for cancer therapy
2024 · Rotta, Giulia
Figure S1 from Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer
2024 · Abdullah Elsayed, Louis Plüss, et al.
Works count: 43
Citation count: 97
H-index: 6
I10-index: 5
Year
Topic
Type